Lipotek is a developer of targeted vaccine delivery and adjuvant technologies.

There is an undeniable need for technological solutions for prophylactic and therapeutic vaccination against pathogens, cancer and other diseases that have limited or no treatment options.

Lipotek is dedicated to developing versatile antigen delivery modules that facilitate dendritic cell (DC) targeting and activation in vivo. DCs are antigen presenting cells that act as key regulators of the immune system. Depending on the antigen environment encountered, they exert either immunogenic or tolerogenic effects. Lipotek's approach to vaccine design is, therefore, to ensure that antigens are delivered to DCs, with simultaneous activation of DCs using cytokines and/or Toll-like receptor (TLR) ligands.

The Lipotek Group website.